Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1

Status

Completed 8Terminated 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Plasma cell 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 1Multiple Myeloma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Has results × L-BLP25 × Clear all
NCT02049151 2017-08-23

START2

EMD Serono

Phase 3 Terminated
35 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01015443 2016-10-26

INSPIRE

Merck KGaA, Darmstadt, Germany

Phase 3 Terminated
285 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01423760 2016-10-06

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Merck KGaA, Darmstadt, Germany

Phase NA Terminated
27 enrolled 7 charts
Plasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma

NCT00925548 2014-07-24

STRIDE

EMD Serono

Phase 3 Terminated
16 enrolled 6 charts
Breast

Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡